COMP <GO>
ICUI vs NVST // RSI-14 & 200D SMA MOMENTUM
ICU Medical Inc. (NASDAQ) VS. Envista Holdings Corporation (NYSE) • 15-METRIC TALLY: ICUI 2
— NVST 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ICUI
LAST: $162.38 (-0.85%) • MKT CAP: $4.10B
rsi-technicals
49.6
LAST: $24.71 (+5.10%) • MKT CAP: $3.78B
rsi-technicals
47.2
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ICUI VS. NVST)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ICUI | NVST | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.80% | 54.70% | -17.90 | NVST | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.00% | 5.10% | -4.10 | NVST | /roic <GO> |
| EV/EBITDA & P/E Valuation | 46.6x | 16.5x | +30.10 | NVST | /valuation <GO> |
| Free Cash Flow Yield | 2.18% | 5.83% | -3.65 | NVST | /fcf-yield <GO> |
| Operating Margin | 1.90% | 7.90% | -6.00 | NVST | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 1.70% | -1.70 | NVST | /net-margins <GO> |
| Revenue Growth (YoY) | -6.30% | 8.30% | -14.60 | NVST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 1.61 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | NVST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 49.6 | 47.2 | +2.40 | ICUI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.93 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 78.2x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.10B | $3.78B | $319.5M | ICUI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ICUI REV | NVST REV | ICUI GROSS % | NVST GROSS % | ICUI FCF | NVST FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.23B | $2.72B | 36.8% | 54.7% | $91.8M | $230.4M |
| FY 2024 | $2.38B | $2.51B | 34.6% | 54.7% | $124.7M | $302.7M |
| FY 2023 | $2.26B | $2.57B | — | — | $166.2M | $160.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ICUI // BETA —
NVST // BETA 0.93